Regulus Therapeutics Inc.

NasdaqCM:RGLS Stock Report

Market Cap: US$104.1m

Regulus Therapeutics Management

Management criteria checks 2/4

Regulus Therapeutics' CEO is Jay Hagan, appointed in May 2017, has a tenure of 7.58 years. total yearly compensation is $2.57M, comprised of 23.9% salary and 76.1% bonuses, including company stock and options. directly owns 0.087% of the company’s shares, worth $90.80K. The average tenure of the management team and the board of directors is 5.3 years and 7.5 years respectively.

Key information

Jay Hagan

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage23.9%
CEO tenure7.6yrs
CEO ownership0.09%
Management average tenure5.3yrs
Board average tenure7.5yrs

Recent management updates

Recent updates

Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth

Sep 28
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth

Regulus surges 15% after Phase 1 data for kidney disease candidate

Sep 12

Regulus Therapeutics GAAP loss per share narrows

Aug 11

Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

Oct 12
Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

The Read On Regulus Therapeutics

Aug 03

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Jun 09
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease

May 03

Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Mar 13
Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Mar 10
Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Regulus Therapeutics announces closing of $19.4M private placement

Dec 08

Regulus Therapeutics EPS beats by $0.17, beats on revenue

Nov 05

CEO Compensation Analysis

How has Jay Hagan's remuneration changed compared to Regulus Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$42m

Jun 30 2024n/an/a

-US$35m

Mar 31 2024n/an/a

-US$31m

Dec 31 2023US$3mUS$616k

-US$30m

Sep 30 2023n/an/a

-US$29m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$1mUS$598k

-US$28m

Sep 30 2022n/an/a

-US$29m

Jun 30 2022n/an/a

-US$30m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$2mUS$568k

-US$28m

Sep 30 2021n/an/a

-US$22m

Jun 30 2021n/an/a

-US$15m

Mar 31 2021n/an/a

-US$16m

Dec 31 2020US$2mUS$552k

-US$16m

Sep 30 2020n/an/a

-US$19m

Jun 30 2020n/an/a

-US$23m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$2mUS$536k

-US$19m

Sep 30 2019n/an/a

-US$22m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$36m

Dec 31 2018US$2mUS$520k

-US$49m

Sep 30 2018n/an/a

-US$55m

Jun 30 2018n/an/a

-US$60m

Mar 31 2018n/an/a

-US$68m

Dec 31 2017US$2mUS$475k

-US$72m

Compensation vs Market: Jay's total compensation ($USD2.57M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Jay's compensation has increased whilst the company is unprofitable.

CEO

Jay Hagan (55 yo)

7.6yrs

Tenure

US$2,574,323

Compensation

Mr. Joseph P. Hagan, also known as Jay, served as Independent Director of Zosano Pharma Corporation since May 22, 2015, until May 10, 2022. He has been the Chief Executive Officer and Director of Regulus T...

Leadership Team

NamePositionTenureCompensationOwnership
Joseph Hagan
CEO & Director7.6yrsUS$2.57m0.087%
$ 90.8k
Crispina Calsada
Chief Financial Officer5.3yrsUS$1.07m0.0088%
$ 9.2k
Christopher Aker
Senior VP13.8yrsUS$1.09m0.015%
$ 16.0k
Preston Klassen
President1.5yrsno data0%
$ 0
Daniel Penksa
VP of Finance & Controller5.4yrsno datano data
Claire Padgett
Senior Vice President of Clinical Operations2.1yrsno datano data
Rekha Garg
Chief Medical Officer2.1yrsno datano data
Edmund Lee
Vice President of Translational Medicineno datano datano data

5.3yrs

Average Tenure

55yo

Average Age

Experienced Management: RGLS's management team is seasoned and experienced (5.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Joseph Hagan
CEO & Director7.6yrsUS$2.57m0.087%
$ 90.8k
Preston Klassen
President1.5yrsno data0%
$ 0
William Rastetter
Independent Director11.7yrsUS$99.44k0.060%
$ 62.1k
Timothy Wright
Member of the Scientific Advisory Board5.8yrsUS$1.48mno data
Stelios Papadopoulos
Independent Chairman of the Board15.9yrsUS$131.44k1.49%
$ 1.6m
David Baltimore
Chairman of the Scientific Advisory Board & Independent Director15.9yrsUS$95.44k0.0039%
$ 4.1k
Jason Nunn
Independent Director5.5yrsUS$97.44k0%
$ 0
Thomas Tuschl
Member of the Scientific Advisory Boardno datano datano data
Markus Stoffel
Member of the Scientific Advisory Boardno datano datano data
Hugh Rosen
Independent Director8.5yrsUS$93.44k0.0027%
$ 2.8k
Kathryn Collier
Independent Director6.7yrsUS$107.44k0.010%
$ 10.7k
Pascale Witz
Independent Director7.5yrsUS$93.44k0.0072%
$ 7.5k

7.5yrs

Average Tenure

61yo

Average Age

Experienced Board: RGLS's board of directors are considered experienced (7.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 22:20
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Regulus Therapeutics Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James BirchenoughBMO Capital Markets Equity Research
James BirchenoughBMO Capital Markets U.S. (Historical)
Madhu KumarB. Riley Securities, Inc.